Eli Lilly and Co (HAM:LLY) Moat Score: 8/10 (As of Jun. 30, 2026)


HAM:LLY Eli Lilly and Co HAM:LLY
98 GF Score
Price €1,081.20
GF Value €1,239.15
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Eli Lilly and Co Moat Score?

Eli Lilly and Co HAM:LLY +4.02% 98 Moat Score is 8 as of Jun. 30, 2026. GuruFocus rates HAM:LLY with a GF Score™ of 98/100 and a GF Value™ of €1,239.15 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 1,030 Drug Manufacturers companies, Eli Lilly and Co ranks better than 99.71% on this metric.

Eli Lilly and Co has the Moat Score of 8, which implies that the company might have Wide Moat - Clear and robust wide moat.

Eli Lilly and Co has Wide Moat: Eli Lilly has a robust wide moat due to its valuable intellectual property, strong brand, and significant R&D capabilities. It benefits from economies of scale, regulatory barriers, and strong pricing power in the pharmaceutical industry.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Eli Lilly and Co might have Wide Moat - Clear and robust wide moat.

Eli Lilly and Co  (HAM:LLY) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Eli Lilly and Co Moat Score Related Terms

HAM:LLY vs JNJ, ABBV, MRK: Moat Score Comparison

For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eli Lilly and Co Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Moat Score distribution charts can be found below:

* The bar in red indicates where Eli Lilly and Co's Moat Score falls into.


HAM:LLY
98GF Score
Eli Lilly and Co HAM:LLY
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 8 mean?
Eli Lilly and Co (HAM:LLY) has a Moat Score of 8 as of Jun. 30, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Eli Lilly and Co ranks #3 out of 1030 companies in the Drug Manufacturers industry, placing it in the top 0.3%.
Is Eli Lilly and Co's Moat Score too high?
Eli Lilly and Co's current Moat Score is 8. Based on the distribution chart, Eli Lilly and Co ranks #3 out of 1030 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Eli Lilly and Co has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eli Lilly and Co's Moat Score compare to JNJ and ABBV?
According to the Drug Manufacturers industry distribution chart, Eli Lilly and Co ranks #3 out of 1030 companies for Moat Score. This places Eli Lilly and Co in the top 0% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Eli Lilly and Co's current Moat Score is 8. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eli Lilly and Co stock overvalued right now?
Based on GuruFocus' analysis, Eli Lilly and Co (HAM:LLY) is currently considered Modestly Undervalued. The stock's GF Value™ is €1,239.15, compared to a current price of €1,081.20 — trading 12.7% below its estimated fair value. The current Moat Score is 8. Eli Lilly and Co's overall GF Score™ is 98/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Eli Lilly and Co (HAM:LLY), the current Moat Score is 8 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Eli Lilly and Co (HAM:LLY) Overvalued in 2026?

Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued. The current stock price of €1,081.20 is trading 12.7% below its estimated GF Value™ of €1,239.15. GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.

Key valuation signals for HAM:LLY:

  • Moat Score: 8
  • GF Value™: €1,239.15 vs. price of €1,081.20 (12.7% below fair value)
  • GF Score™: 98/100 with 6 warning signs

No single metric tells the full story. See the HAM:LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Eli Lilly and Co Business Description

Address Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
98GF Score

Get the complete analysis for HAM:LLY

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1,081.20
Price
€1,239.15
GF Value